Evidence map›Paper›PMID 24595008›Full record

ArticlePloS one2014

Variations in the MHC region confer risk to esophageal squamous cell carcinoma on the subjects from high-incidence area in northern China.

Fang-Fang Shen, Wen-Bin Yue, Fu-You Zhou, Ying Pan, Xue-Ke Zhao, Yan Jin, Xin Song, Bei Li, Xue-Na Han, Sa Tang and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Fang-Fang ShenHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China; Cancer Research Center and the Third Affiliated Hospital, Xinxiang Medical University, Xinxiang, Henan, China.
Wen-Bin YueHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Fu-You ZhouDepartment of Thoracic Surgery, Anyang Tumor Hospital, Anyang, Henan, China.
Ying PanCancer Research Center and the Third Affiliated Hospital, Xinxiang Medical University, Xinxiang, Henan, China.
Xue-Ke ZhaoHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Yan JinHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Xin SongHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Bei LiHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Xue-Na HanHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Sa TangHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Yan LiHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Guo YuanHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China; Cancer Research Center and the Third Affiliated Hospital, Xinxiang Medical University, Xinxiang, Henan, China.
Li-Sha ChenHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China; Cancer Research Center and the Third Affiliated Hospital, Xinxiang Medical University, Xinxiang, Henan, China.
Ya-Li LiuHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China; Cancer Research Center and the Third Affiliated Hospital, Xinxiang Medical University, Xinxiang, Henan, China.
Yan-Long HuHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China; Cancer Research Center and the Third Affiliated Hospital, Xinxiang Medical University, Xinxiang, Henan, China.
Xiu-Min LiCancer Research Center and the Third Affiliated Hospital, Xinxiang Medical University, Xinxiang, Henan, China.
Jing-Li RenDepartment of Pathology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Li-Dong WangHenan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Zhengzhou University · CNXinxiang Medical University · CNAnyang Tumor Hospital · CNSecond Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe human major histocompatibility complex (MHC) is the most important region in vertebrate genome, and is crucial in innate immunity. Recent studies have demonstrated the possible role of polymorphisms in the MHC region to high risk for esophageal squamous cell carcinoma (ESCC). Our previous genome-wide association study (GWAS) has indicated that the MHC region may confer important risk loci for ESCC, but without further fine mapping. The aim of this study is to further identify the risk loci in the MHC region for ESCC in Chinese population.

methodsConditional logistic regression analysis (CLRA) was performed on 24 single nucleotide polymorphisms (SNPs) within the MHC region, which were obtained from the genetically matched 937 cases and 692 controls of Chinese Han population. The identified promising SNPs were further correlated with clinical and clinicopathology characteristics. Immunohistochemistry was performed to explore the protein expression pattern of the related genes in ESCC and neighboring normal tissues.

resultsOf the 24 promising SNPs analyzed, we identified three independent SNPs in the MHC region associated with ESCC: rs35399661 (P = 6.07E-06, OR = 1.71, 95%CI = 1.36-2.17), rs3763338 (P = 1.62E-05, OR = 0.63, 95%CI = 0.50-0.78) and rs2844695 (P = 7.60E-05, OR = 0.74, 95%CI = 0.64-0.86). These three SNPs were located at the genes of HLA-DQA1, TRIM27, and DPCR1, respectively. Further analyses showed that rs2844695 was preferentially associated with younger ESCC cases (P = 0.009). The positive immunostaining rates both for HLA-DQA1 and TRIM27 were much higher in ESCC tissues than in neighboring normal tissues (69.4% vs. 26.8% for HLA-DQA1 and 77.6% vs. 47.8% for TRIM27, P<0.001). Furthermore, the overexpression of HLA-DQA1 is correlated significantly with age (P = 0.001) and family history (P<0.001).

conclusionThis study for the first time provides evidence that multiple genetic factors within the MHC region confer risk to ESCC on the subjects from high-risk area in northern China.

Indexed as

Genetic Predisposition to DiseaseCarcinoma, Squamous CellChinaDNA-Binding ProteinsEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGenotyping TechniquesHLA-DQ alpha-ChainsHumansImmunohistochemistryIncidenceLinkage DisequilibriumLogistic ModelsMajor Histocompatibility ComplexNuclear ProteinsPolymorphism, Single NucleotideDNA-Binding ProteinsHLA-DQA1 antigenHLA-DQ alpha-ChainsNuclear ProteinsTRIM27 protein, humanTripartite Motif Proteins

Identifiers

PMID24595008
PMCPMC3942432
OpenAlexW1966469585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.